Penserra Capital Management’s Travere Therapeutics TVTX Stock Holding History

Penserra Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.08M	Buy	+54,216	New	+$2.4M	0.02%	318
2026 Q1	–	Sell	-79,747	Closed	-$3.05M	–	1183
2025 Q4	$3.05M	Sell	79,747 -809	-1%	-$26.3K	0.04%	309
2025 Q3	$1.93M	Buy	+80,556	New	+$1.51M	0.02%	342
2025 Q2	–	Sell	-109,542	Closed	-$1.96M	–	1136
2025 Q1	$1.96M	Buy	+109,542	New	+$2.22M	0.04%	304
2021 Q4	–	Sell	-1,390	Closed	-$33K	–	1551
2021 Q3	$33K	Buy	1,390 +15	+1%	+$276	﹤0.01%	1166
2021 Q2	$20K	Buy	1,375 +75	+6%	+$1.48K	﹤0.01%	1152
2021 Q1	$32K	Buy	1,300 +130	+11%	+$3.59K	﹤0.01%	894
2020 Q4	$31K	Buy	1,170 +736	+170%	+$17.2K	﹤0.01%	771
2020 Q3	$8K	Buy	+434	New	+$8.44K	﹤0.01%	841

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Penserra Capital Management's TVTX Position: Q2 2026 in Review

Penserra Capital Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 54,216 shares worth $3.08M. The stake represents 0.02% of the portfolio and ranks #318 among its holdings. This is a return to the name: Penserra Capital Management previously reported a position in TVTX as recently as Q4 2025.

Penserra Capital Management first reported a position in TVTX in Q3 2020 and has held it in 9 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Penserra Capital Management held 54,216 shares of Travere Therapeutics worth $3.08M as of Q2 2026.
Travere Therapeutics was a new Penserra Capital Management position in Q2 2026.
Travere Therapeutics made up 0.02% of Penserra Capital Management's portfolio in Q2 2026, its #318 holding.
Penserra Capital Management first reported a position in Travere Therapeutics in Q3 2020 and has held it in 9 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.